While the role of epigenetic modifications in kidney diseases has been extensively studied , its link to sex hormones is still anecdotal and would require further investigation. The sex-related discrepancies observed in clinical and experimental settings of CKD and prominent kidney diseases causing CKD can be explained in part by the effect of sex hormones on the kidney. Although the evidence mentioned above has provided valuable information on the direct and indirect effects of estrogens in the kidney, further research is needed to clarify the relationship between sex hormones and the incidence and progression of diabetic renal disease. By combining gonadal hormones and sex hormone receptor deletions with existing experimental models of renal disease, it may be possible to develop valuable tools for studying sex differences. As many germline loss-of-function mutations in the sex hormone receptors in mouse models lack renal phenotypes, it is conceivable that abnormalities may only become evident under physiological stress, with age, or following kidney injury. Testosterone is also known as the hormone of vitality. Testosterone levels have shown a difference in the progression of CKD by gender. This may be of crucial importance in understanding the observed sex differences in vulnerability to CKD and suggests that this may be an important dimension to be considered in future research into the development and progression of CKD. It is also unclear if a sustained exposure to testosterone may have irreversible effects. Physiological changes of testosterone during puberty may have a much more blunted effect. There are several limitations, mostly due to the fact that a single case is presented without confirming the effects in other subjects, and the fact that a therapeutic testosterone dose was administered for the purpose of inducing puberty in a single dose rather than gradually increasing testosterone concentrations. Another strength lies is the objective confirmation of renal perfusion changes by taking advantage of cutting-edge developments in both imaging technology and sequence development. We used the previously published 125 genome-wide significant SNPs for bioavailable testosterone in men and 254 SNPs for total testosterone in women. For validation, we examined the association of genetically predicted testosterone with hemoglobin and HDL-cholesterol as positive controls. The genetic predictors for testosterone were as used in univariable MR. The genetic predictors for SHBG were provided by the GWAS in the UK Biobank, with 357 SNPs in men and 359 SNPs in women . The GWAS also provided 231 independent SNPs for total testosterone in men and 180 independent SNPs for bioavailable testosterone in women , which are highly correlated with SHBG . For validation, we assessed the associations of genetically predicted testosterone with hemoglobin and HDL-cholesterol; a finding consistent with well-established effects in RCTs provides some validation of the genetic instrument. For example, in vitro experiments show testosterone induced renal tubular epithelial cell death in a dose-response manner . From the perspective of evolutionary biology, growth and reproduction trade off against longevity, with men and women having different investments in these trade-offs and as a result have different vulnerabilities to disease 4–6. Studies suggest that men with low testosterone are more likely to develop type 2 diabetes. However, this effect is not guaranteed in all patients and depends on many factors like age, activity level, and other medical problems. These changes can reduce the pressure placed on the kidneys over time. Hypogonadism itself causes homeostasis disorders such as obesity, metabolic syndrome, anaemia, decrease of libido and erectile dysfunction, and a decrease of lean tissue mass and muscle strength 5,6,7,8,9. The incidence of hypogonadism in CKD patients stands at 27 to 66% . One of the endocrinological disorders which develop in association with CKD is hypogonadism . (Conclusions) The applied model of TRT is effective in the correction of clinical signs of hypogonadism without a significant risk of overhydration or PSA changes. Serum total testosterone level (TT) was measured, and free testosterone level (fT) was calculated. However, testosterone therapy is not a cure for CKD, and it should not be seen as a way to reverse kidney damage. This is because testosterone helps the body make more red blood cells. Other studies suggest that testosterone therapy may reduce protein in the urine, also known as proteinuria. One area of interest is how testosterone may improve renal blood flow. Several studies have looked at men with low testosterone and CKD to see what happens when they receive testosterone therapy. Several methods for measuring serum testosterone were reported, including enzyme immunoassay (ELISA), liquid chromatography-tandem mass spectrometry, and radioimmunoassay (RIA) techniques. The other nine studies investigated the association of testosterone status with clinical outcomes in men with moderate or severe CKD (stage G3–G5), although one of them included men with mild CKD as well (stage G1–G2) (27). The used term ‘serum testosterone’ is about serum total testosterone, serum free testosterone is indicated as such. Testosterone is a hormone made mainly in the testicles in males and in smaller amounts by the ovaries in females. Careful monitoring and regular check-ups help reduce these risks and keep treatment safe. Fluid retention, high blood pressure, and thickened blood are the main concerns. But in these cases, treatment must be closely watched by a healthcare provider. This allowed an in vivo assessment of renal blood flow, patterns of renal perfusion, and other functional parameters of the kidneys in previously unobtainable detail. Long-term studies are important to better understand how testosterone therapy affects the kidneys over time. The link between testosterone and kidney function is complex, and more research is still needed.